Positron Emission Tomography (PET) Using Hormone Receptor Ligands in Breast Cancer

Inclusion Criteria:

• Male and Female patients
• Aged 18 or older at the time of breast cancer diagnosis
• Patients with invasive breast cancer at least 1 cm in size. Patients who have had a prior surgical excision are eligible provided there is a residual of at least a 1 cm area suspected on imaging studies.
• Histopathologic review at MSKCC confirming diagnosis of invasive breast cancer (ductal, lobular, or inflammatory breast cancer).
• Patients who are operative candidates. Patient will have surgery to include either mastectomy or lumpectomy. Radiologic assisted excisions such as needle localization are also eligible.
• Patients with bilateral breast cancer are eligible.
• Patients with metastatic cancer, provided they need surgical biopsy.
• Patients who are undergoing sentinel node mapping (day before or sameday mapping).
• Patient must sign informed consent.

Exclusion Criteria:

• Previous or concurrent malignancy (except basal and squamous skin cancer and stage 0 cervical cancer)
• Patients who are pregnant or nursing
• Patients unable to tolerate PET or PET/CT
• Patients with known active infection, autoimmune or inflammatory disease such as sarcoidosis, and rheumatoid arthritis.
• Patients with non invasive breast cancer such as DCIS.
• Patients who have received prior radiation therapy to the affected breast.
• Patients who have received prior chemotherapy, including neoadjuvant chemotherapy or hormonal therapy for breast cancer.
• Patients living in a residential care or correctional facility.